

IDSAP 2021 Book 1 (*Cardiopulmonary Infections*)

Release date: November 15, 2021

BCIDP test deadline: 11:59 p.m. (Central) on May 16, 2022.

ACPE test deadline: 11:59 p.m. (Central) on November 15, 2024.



Continuing Pharmacy Education Credit: The American College of Clinical Pharmacy

and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education (CPE).

IDSAP Target Audience: The target audience for IDSAP 2021 Book 2 (*Cardiopulmonary Infections*) is board-certified infectious diseases pharmacists caring for patients with complex cardiopulmonary infections.

Module 1 (4.5 CPE) Cardiopulmonary Infections I

UAN: 0217-9999-21-262-H01-P

Chapter: Infective Endocarditis

Learning Objectives

1. Evaluate patients for causative pathogens based on risk factors associated with infective endocarditis.
2. Evaluate patients for the pathophysiology of infective endocarditis.
3. Assess a patient for infective endocarditis based on clinical presentation and diagnostics.
4. Design an antimicrobial treatment plan for a patient with infective endocarditis including drug selection, dosing, and duration of therapy.

Chapter: Implantable Cardiac-Assist Devices and Vascular Graft Infections

Learning Objectives

1. Evaluate the risk factors and diagnostic techniques used to identify cardiac-assist device and vascular graft infections.
2. Assess patients for the pathophysiology and microbiology associated with cardiac-assist device and vascular graft infections.
3. Design an antimicrobial treatment plan for a patient with a cardiac assist device or vascular graft infections.
4. Assess patients for complications associated with device-related infections and design prevention strategies.

Module 2 (5.0 CPE) Cardiopulmonary Infections II

UAN: 217-9999-21-263-H01-P

Chapter: Infections in Persons Who Inject Drugs

Learning Objectives

1. Develop prophylactic and treatment regimens against HIV infection, including counseling and monitoring parameters.
2. Design a screening and treatment approach for hepatitis in persons who inject drugs (PWID).
3. Design antimicrobial treatment and monitoring regimens for skin and soft tissue infections (SSTIs), endocarditis, and osteoarticular infections in PWID.
4. Evaluate screening, treatment, and prevention strategies for SSTIs based on risk factors.
5. Design a therapeutic plan for the treatment of tuberculosis, including assessments and mitigation of drug interactions.
6. Evaluate harm-reduction strategies and assess patients for logistical roadblocks commonly encountered with implementation of those strategies in PWID.

Chapter: Diagnostic Testing for Bacterial Pneumonia

Learning Objectives

1. Assess patients for clinical signs and symptoms of pneumonia.
2. Evaluate available culture and non-culture-based methods for the diagnosis of pneumonia.
3. Justify appropriate diagnostic testing for suspected pneumonia, given host-specific factors and presentation.
4. Apply principles of diagnostic stewardship in practice to optimize management for patients with suspected pneumonia.

Module 3 (4.5 CPE) Cardiopulmonary Infections III

UAN: 217-9999-21-263-H01-P

Chapter: Bacterial Pneumonia Treatment

Learning Objectives

1. Evaluate the microbiology, epidemiology, and clinical presentation in patients with pneumonia.
2. Evaluate patient populations at greatest risk of multidrug-resistant pneumonia.
3. Design an antimicrobial treatment plan for outpatients and inpatients with pneumonia.
4. Justify the role of antimicrobial stewardship and the pharmacist in treating patients with pneumonia; distinguish patients who are eligible for short-course therapy.

Chapter: Viral Pneumonia

Learning Objectives (A)

1. Design a treatment plan for patients with seasonal influenza infection on the basis of patient-specific factors.
2. Evaluate treatment options for respiratory syncytial virus, and distinguish the differences in approach in the treatment of adult versus pediatric populations.
3. Distinguish among the viral pathogens causing respiratory illness in immunocompetent and immunocompromised patients, and develop management plans.
4. Evaluate antimicrobial stewardship studies targeting antibiotic de-escalation in patients with viral respiratory tract infections, and identify areas for future study.

Module 4 (3.0 CPE) Cardiopulmonary Infections IV

UAN: 0217-9999-21-265-H01-P

Interactive Cases: Stewardship Interventions for Optimizing Pneumonia Treatment

Learning Objectives

1. Design appropriate treatment plans for patients at risk for community-acquired pneumonia with *Pseudomonas aeruginosa* and *methicillin-resistant Staphylococcus aureus*.
2. Justify an appropriate duration of antibiotic therapy for patients with community-acquired pneumonia based on clinical response and other patient-specific factors.
3. Design preferred antimicrobial stewardship action interventions based on recommendations from the CDC Antibiotic Stewardship Core Elements for Acute Care Hospitals.

Interactive Case: Upper Respiratory Tract Infection Stewardship Interventions

Learning Objectives (A)

1. Distinguish between viral and bacterial upper respiratory tract infections (URIs).
2. Apply the Joint Commission's core elements of performance for outpatient antimicrobial stewardship to the development of an outpatient antimicrobial stewardship initiative.
3. Design an appropriate pharmacotherapy plan for a patient with URI symptoms.
4. Design an antimicrobial stewardship intervention aimed at improving appropriate antibiotic prescribing for URIs.
5. Evaluate URI treatment in patients with penicillin allergies who may be eligible for cephalosporin therapy.